The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.

Personalized medicine aims to tailor treatments to individual patients. Until now, this has been done using a small number of parameters to predict the course of a disease.

The immediate threat has passed, at least for now. But concern from individuals, businesses, nonprofits and local governments ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Women's pain is often misdiagnosed or ignored. But what's being done about it? We asked women and MDs to weigh in on.

Billed as the most significant change to the science system in 30 years, last week's announcement of major structural changes to scientific research institutions was objectively a big deal.

A new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of ...

The integration of the Internet of Things (IoT) into the field of medicine marks a pivotal advancement in modern healthcare. By connecting devices, sensors, ...

Over the past decade, medical research and testing have increasingly focused on adopting human biology-based methods.

Doctors take an oath to “do no harm.” That sadly doesn’t apply to the Trump administration officials who have thrown ...

The interim leader of the National Institutes of Health gave some clarification tied to Trump administrations restrictions on ...

When research is stopped, or even paused, it has real effects on our lives. It means that a cure for the diabetes that runs in your family will be delayed. It means that efforts to understand how ...